Literature DB >> 17256155

Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia.

Justine A Ellis1, Katrina J Scurrah, Joanna E Cobb, Sophie G Zaloumis, Anna E Duncan, Stephen B Harrap.   

Abstract

Androgenetic alopecia, or male pattern baldness, is a complex condition with a strong heritable component. In 2001, we published the first significant evidence of a genetic association between baldness and a synonymous coding SNP (rs6152) in the androgen receptor gene, AR. Recently, this finding was replicated in three independent studies, confirming an important role for AR in the baldness phenotype. In one such replication study, it was claimed that the causative variant underlying the association was likely to be the polyglycine (GGN) repeat polymorphism, one of two apparently functional triplet repeat polymorphisms located in the exon 1 transactivating domain of the gene. Here, we extend our original association finding and present comprehensive evidence from approximately 1,200 fathers and sons drawn from 703 families of the Victorian Family Heart Study, a general population Caucasian cohort, that neither exon 1 triplet repeat polymorphism is causative in this condition. Seventy-eight percent of fathers (531/683) and 30% of sons (157/520) were affected to some degree with AGA. We utilised statistical methods appropriate for the categorical nature of the phenotype and familial structure of the cohort, and determined that whilst SNP rs6152 was strongly associated with baldness (P < 0.0001), the GGN triplet repeat was not (P = 0.13). In the absence of any other known common functional coding variants, we argue that the causative variant is likely to be in the non-coding region, and yet to be identified. The identification of functional non-coding variants surrounding AR may have significance not only for baldness, but also for the many other complex conditions that have thus far been linked to AR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17256155     DOI: 10.1007/s00439-006-0317-8

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  20 in total

1.  GOLD--graphical overview of linkage disequilibrium.

Authors:  G R Abecasis; W O Cookson
Journal:  Bioinformatics       Date:  2000-02       Impact factor: 6.937

2.  Genetic basis of male pattern baldness.

Authors:  Dale R Nyholt; Nathan A Gillespie; Andrew C Heath; Nicholas G Martin
Journal:  J Invest Dermatol       Date:  2003-12       Impact factor: 8.551

3.  Male pattern baldness: classification and incidence.

Authors:  O T Norwood
Journal:  South Med J       Date:  1975-11       Impact factor: 0.954

4.  Assessing proportionality in the proportional odds model for ordinal logistic regression.

Authors:  R Brant
Journal:  Biometrics       Date:  1990-12       Impact factor: 2.571

5.  Reduced androgen receptor gene expression with first exon CAG repeat expansion.

Authors:  C S Choong; J A Kemppainen; Z X Zhou; E M Wilson
Journal:  Mol Endocrinol       Date:  1996-12

6.  Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia.

Authors:  Axel M Hillmer; Sandra Hanneken; Sibylle Ritzmann; Tim Becker; Jan Freudenberg; Felix F Brockschmidt; Antonia Flaquer; Yun Freudenberg-Hua; Rami Abou Jamra; Christine Metzen; Uwe Heyn; Nadine Schweiger; Regina C Betz; Bettina Blaumeiser; Jochen Hampe; Stefan Schreiber; Thomas G Schulze; Hans Christian Hennies; Johannes Schumacher; Peter Propping; Thomas Ruzicka; Sven Cichon; Thomas F Wienker; Roland Kruse; Markus M Nothen
Journal:  Am J Hum Genet       Date:  2005-05-18       Impact factor: 11.025

7.  Effect of a short CAG (glutamine) repeat on human androgen receptor function.

Authors:  Dacheng Ding; Lihua Xu; Mani Menon; G Prem Veer Reddy; Evelyn R Barrack
Journal:  Prostate       Date:  2004-01-01       Impact factor: 4.104

8.  The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function.

Authors:  N L Chamberlain; E D Driver; R L Miesfeld
Journal:  Nucleic Acids Res       Date:  1994-08-11       Impact factor: 16.971

9.  Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies.

Authors:  P Kazemi-Esfarjani; M A Trifiro; L Pinsky
Journal:  Hum Mol Genet       Date:  1995-04       Impact factor: 6.150

10.  Validity of self reported male balding patterns in epidemiological studies.

Authors:  Rosalind Taylor; Julia Matassa; Justine E Leavy; Lin Fritschi
Journal:  BMC Public Health       Date:  2004-12-13       Impact factor: 3.295

View more
  15 in total

Review 1.  Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.

Authors:  Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

2.  Hormones and the pilosebaceous unit.

Authors:  Wen-Chieh Chen; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2009-03

Review 3.  Androgenetic alopecia: a review.

Authors:  Francesca Lolli; Francesco Pallotti; Alfredo Rossi; Maria C Fortuna; Gemma Caro; Andrea Lenzi; Andrea Sansone; Francesco Lombardo
Journal:  Endocrine       Date:  2017-03-28       Impact factor: 3.633

4.  Ancient human genome sequence of an extinct Palaeo-Eskimo.

Authors:  Morten Rasmussen; Yingrui Li; Stinus Lindgreen; Jakob Skou Pedersen; Anders Albrechtsen; Ida Moltke; Mait Metspalu; Ene Metspalu; Toomas Kivisild; Ramneek Gupta; Marcelo Bertalan; Kasper Nielsen; M Thomas P Gilbert; Yong Wang; Maanasa Raghavan; Paula F Campos; Hanne Munkholm Kamp; Andrew S Wilson; Andrew Gledhill; Silvana Tridico; Michael Bunce; Eline D Lorenzen; Jonas Binladen; Xiaosen Guo; Jing Zhao; Xiuqing Zhang; Hao Zhang; Zhuo Li; Minfeng Chen; Ludovic Orlando; Karsten Kristiansen; Mads Bak; Niels Tommerup; Christian Bendixen; Tracey L Pierre; Bjarne Grønnow; Morten Meldgaard; Claus Andreasen; Sardana A Fedorova; Ludmila P Osipova; Thomas F G Higham; Christopher Bronk Ramsey; Thomas V O Hansen; Finn C Nielsen; Michael H Crawford; Søren Brunak; Thomas Sicheritz-Pontén; Richard Villems; Rasmus Nielsen; Anders Krogh; Jun Wang; Eske Willerslev
Journal:  Nature       Date:  2010-02-11       Impact factor: 49.962

5.  Relationship of early-onset baldness to prostate cancer in African-American men.

Authors:  Charnita Zeigler-Johnson; Knashawn H Morales; Elaine Spangler; Bao-Li Chang; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-26       Impact factor: 4.254

6.  Relationship between male pattern baldness and the risk of aggressive prostate cancer: an analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Cindy Ke Zhou; Ruth M Pfeiffer; Sean D Cleary; Heather J Hoffman; Paul H Levine; Lisa W Chu; Ann W Hsing; Michael B Cook
Journal:  J Clin Oncol       Date:  2014-09-15       Impact factor: 44.544

Review 7.  Finasteride in Hidradenitis Suppurativa: A "Male" Therapy for a Predominantly "Female" Disease.

Authors:  Birgit N Khandalavala; Melissa Voutsalath Do
Journal:  J Clin Aesthet Dermatol       Date:  2016-06-01

8.  Androgen receptor copy number variation and androgenetic alopecia: a case-control study.

Authors:  Joanna E Cobb; Stefan J White; Stephen B Harrap; Justine A Ellis
Journal:  PLoS One       Date:  2009-04-02       Impact factor: 3.240

9.  Recent positive selection of a human androgen receptor/ectodysplasin A2 receptor haplotype and its relationship to male pattern baldness.

Authors:  Axel M Hillmer; Jan Freudenberg; Sean Myles; Stefan Herms; Kun Tang; David A Hughes; Felix F Brockschmidt; Yijun Ruan; Mark Stoneking; Markus M Nöthen
Journal:  Hum Genet       Date:  2009-04-17       Impact factor: 4.132

10.  "Cold" X5 Hairlaser™ used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study.

Authors:  Kenneth Blum; David Han; Margaret A Madigan; Raquel Lohmann; Eric R Braverman
Journal:  BMC Res Notes       Date:  2014-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.